Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Clinical Study to Evaluate the Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors

NCT05166070 is registered in ClinicalTrials.gov with The First Affiliated Hospital with Nanjing Medical University as lead sponsor.

NCT NCT05166070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05166070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Clinical Study to Evaluate the Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
Phase
Phase 1
Overall status
Recruiting
Start date
January 1, 2022
Completion date
January 1, 2037
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor